Key clinical point: Some physician-authors of American College of Rheumatology clinical practice guidelines are not fully disclosing their financial conflicts of interest, which may impact their decisions when making guideline recommendations.

Major finding: Since 2014, 56 of 89 total physician-authors across five ACR guidelines have been paid a total of $9,728,751 from industry sources. Nineteen of 89 authors received $1,961,362 in industry payments that were directly relevant to a guideline’s recommendations, and $699,561 of these payments (35.7%) were undisclosed.

Study details: An analysis of industry payments made to 89 physician-authors of five ACR clinical practice guidelines since 2014.

Disclosures: The authors reported having no funding source for the study. One author reported serving on an advisory board for Janssen involving infliximab and golimumab, for Sanofi Genzyme involving sarilumab, and receiving payment for a survey from Comsort. The other authors reported having no conflicts of interest.